At inception, BioPAD had a broad portfolio of projects in mining, environment, industrial and animal health biotechnologies. A number of these investments have been completed at a project level and are ready for exploitation and some of the technologies have entered the market place.
New projects have a strong
focus on different areas of health biotechnology:
diagnostics, drug discovery and development,
vaccines and bioprocess technologies.
| BioPAD Current Portfolio |
Development stage |
Expected outcomes |
|
Projects
|
| Glycoengineering (Bioprocessing) |
Early R&D |
Recombinant yeast for glycosylation of
human proteins |
| Anti-HIV (Preclinical drug development) |
Early R&D |
Chemical and preclinical characterisation
of medicinal plants |
| Anti-cancer (Preclinical drug development) |
Early-Middle R&D |
Preclinical development of anticancer
leads, limited Phase I clinical trials |
| |
|
|
|
Platforms
|
| Microarray (Genomics R&D) |
Early R&D |
Protocol development and human capacity
development |
| Metabolomics (Diagnostics/service delivery) |
Early R&D |
Robust diagnostics for metabolite screening,
commercial services |
| Drug delivery products (Drug delivery) |
Early-Middle R&D |
Various drug delivery products |
| Metagenomics (Genomics R&D) |
Early R&D |
Cloning and expression of genes from extreme
environments |
| |
|
|
|
Companies
|
| iSlices |
Product in market |
Manufacturing and distribution of iSlices
products |
| Inqaba (Genomics service business) |
Commercial services |
Primers and routine DNA sequencing, distributors
of biotech reagents |
| BioPAD infrastructure investment |
Commercial services |
High-throughput DNA sequencing service
in partnership with Inqaba |
| Mycoroot (manufacturing/sales) |
Product in market |
Manufacturing of mycorrhiza fertilizer |
| Origin Source (nutraceuticals) |
Late-market launch |
Sales and distribution of mushroom based
nutraceuticals |
| The AloeferoxCo |
Product in market |
Sales of aloesin API and formulated products |
| Mbuyu (Biocatalysis and bioprocessing) |
Middle-late R&D |
Platform technologies: immobilised enzymes,
bacterial expression system |
| iThemba (Medicinal chemistry) |
Middle R&D |
Medicinal chemistry of leads targeting
latent MTb; novel ARV synthesis |
| Ribotech (Manufacturing/sales) |
Late-market |
Manufacturing and distribution/sales of
clinical doses of rHuman G-CSF |
| Completed projects |
Outcomes |
Commercialisation status |
| Molecular diagnostic kits for tick borne
pathogens |
RLB kit /RT-PCR assay |
Kit in the market, tech transfer to OVI |
| Biocatalytic value addition to aloe bitters
refining |
Product |
Licensed to The AloeferoxCo |
| Aquaculture |
Product |
Licensed to BaoBio (Pty) Ltd |
| Production of food and perfumery flavours
from microorganisms |
Product |
Available for licensing |
| Beneficiation of plant products to improve
animal health/production |
Products and publications |
Not yet commercialised |
| Novel virus protein particles |
Patent filed/publications |
Not yet commercialised |
| Microbial enzymes for Rooibos processing
|
Patents filed |
In the process of commercialisation |
| Inoculation of bio-assisted heap leaching
operations |
Patent filed |
Not yet commercialised |
| Bioleaching for zinc sulphide |
Patent filed |
Not yet commercialised |
| Reduction of sulphate in acid mine drainage |
Technical report |
Not yet commercialised |
| The Rhodes BioSure process |
Technology package |
Licensed to ERWAT |
